Fiche publication
Date publication
janvier 2020
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GACHET Christian
,
Dr MANGIN Pierre
Tous les auteurs :
Do Sacramento V, Mallo L, Freund M, Eckly A, Hechler B, Mangin P, Lanza F, Gachet C, Strassel C
Lien Pubmed
Résumé
The in vitro production of blood platelets for transfusion purposes is an important goal in the context of a sustained demand for controlled products free of infectious, immune and inflammatory risks. The aim of this study was to characterize human platelets derived from CD34 progenitors and to evaluate their hemostatic properties. These cultured platelets exhibited a typical discoid morphology despite an enlarged size and expressed normal levels of the major surface glycoproteins. They aggregated in response to ADP and a thrombin receptor agonist peptide (TRAP). After infusion into NSG mice, cultured and native platelets circulated with a similar 24 h half-life. Notably, the level of circulating cultured platelets remained constant during the first two hours following infusion. During this period of time their size decreased to reach normal values, probably due to their remodeling in the pulmonary circulation, as evidenced by the presence of numerous twisted platelet elements in the lungs. Finally, cultured platelets were capable of limiting blood loss in a bleeding assay performed in thrombocytopenic mice. In conclusion, we show here that cultured platelets derived from human CD34 cells display the properties required for use in transfusion, opening the way to clinical trials.
Référence
Sci Rep. 2020 Jan 22;10(1):914
